Abstract:Epilepsy Currents, Ahead of Print. Empiric Dosing Strategies to Predict Lamotrigine Concentrations During Pregnancy Barry JM, French JA, Pennell PB, Karanam A, Harden CL, Birnbaum AK. Pharmacotherapy. 2023;43(10):998-1006. doi:10.1002/phar.2856. PMID: 37475496 Introduction:Maintaining seizure control with lamotrigine is complicated by altered pharmacokinetics and existence of subpopulations in whom clearance increases or remains constant during pregnancy.Objective:Our objective was to characterize the potential for particular dosing scenarios to lead to increased seizure risk or toxicity.Methods:Lamotrigine pharmacokinetic parameters obtained from our previous study were applied to a one-compartment model structure with subpopulations (75:25%) exhibiting different clearance changes. A single-patient simulation was conducted with typical pharmacokinetic parameter values from each subpopulation. Population-level simulations (N = 48,000) included six dosing scenarios and considered four preconception doses using the R package mrgsolve (Metrum Research Group). Thresholds for efficacy and toxicity were selected as drug concentration that are 65% lower than preconception concentrations and doubling of preconception concentrations, respectively.Results:Individual simulation results demonstrated that without dose increases, concentrations fell below 0.65 at 6-8 weeks in the high clearance change (HC) subpopulation, depending on preconception clearance. While no simulated dosing regimen allowed all women in both subpopulations to maintain preconception concentrations, some regimens provided a more balanced risk profile than others. Predicted concentrations suggested potential increased seizure risk for 7%-100% of women in the HC group depending on preconception dose and subpopulation. Additionally, in 63% of dosing scenarios for women with low clearance change (LC), there was an increased risk of toxicity (34%-100% of women).Significance:A substantial percentage of simulated individuals had concentrations low enough to potentially increase seizure risk or high enough to create toxicity. Early clearance changes indicate possible subpopulation categorization if therapeutic drug monitoring is conducted in the first trimester. An arbitrary "one-size-fits-all" philosophy may not work well for lamotrigine dosing adjustments during pregnancy and reinforces the need for therapeutic drug monitoring until a patient is determined to be in the LC or HC group.

Effect of Oral Contraceptives on Lamotrigine Levels Depends on Comedication.

Influence of Concomitant Antiepileptic Drugs on Lamotrigine Plasma Concentration in Children with Epilepsy

Specific OCT1 and ABCG2 Polymorphisms Are Associated with Lamotrigine Concentrations in Chinese Patients with Epilepsy

Drug Monitoring of Lamotrigine and Oxcarbazepine Combination During Pregnancy

Ethosuximide lowers lamotrigine serum concentrations: Evidence for a clinically relevant interaction

Concomitant lamotrigine use is associated with decreased efficacy of the ketogenic diet in childhood refractory epilepsy

The Study for the Relation Between the Serum Concentration of Lamotrigine and its Effect

The Impact of Age on Lamotrigine and Oxcarbazepine Kinetics: a Historical Cohort Study.

Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling

Effect of Genetic Polymorphisms of ABCB1, ABCG2, and SLC22A1 on the Steady-State Plasma Concentrations of Lamotrigine in Treatment-Resistant Depressed Patients Treated With Lamotrigine Augmentation Therapy

Step Climb Dosing Guidance From Simulation Studies on Lamotrigine Concentration Changes During Pregnancy

Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy

Polymorphisms of ABCG2 , ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients

Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either Valproate or Lamotrigine monotherapy: A prospective study

Relationship between the genetic factors and lamotrigine efficacy in epileptic children received valproic ac-id therapy in south China

Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine

Effect of Lamotrigine on Quality of Life in Patients with Newly Diagnosed Epilepsy

Association of Ventricular Arrhythmias with Lamotrigine: An Observational Cohort Study

Effects of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Pharmacokinetics of Lamotrigine and Valproate: A Cohort Study

Effects of Lamotrigine on Serum Thyroid Hormone Levels in Patients with Epilepsy

Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy